Search Active Studies

Cedar Crosse Research Center connects patients with personalized health supervision through comprehensive clinical research studies.

Cedar Crosse’s clinical trials in diabetes, hypertension, hyperlipidemia, migraine headache, Alzheimer’s, depression, HIV, Obesity, Hepatitis and insomnia are advancing new treatments in medicine. Led by Dr. Danny H. Sugimoto, the experienced and caring Cedar Crosse Research team has conducted over 400 clinical trials serving most major pharmaceutical companies.

With an unmatched commitment to research excellence and quality patient attention, Cedar Crosse is furthering the development of new medicine treatment of patients, and health of the world.

Are migraines constantly on your mind?


Inclusion Criteria:

- Males and females between 18 and 65 years of age, inclusive, who were diagnosed with migraines at ≤ 50 years of age, and have a history of chronic migraine for ≥ 12 months before screening.
-During the 28 day screening period, subjects must adequately complete the headache eDiary and must have headaches occurring on ≥ 15 to ≤ 26 days of which at least 8 must be migraine days.

Exclusion Criteria:

- Confounding and clinically significant pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome).
- Psychiatric conditions that are uncontrolled and/or untreated, including conditions that are not controlled for a minimum of 6 months prior to screening. -
- Patients with a lifetime history of psychosis, mania, or dementia are excluded.
- Any use of botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections within 4 months prior to screening and during the screening period.
- History or diagnosis of complicated migraine (ICHD-III beta version, 20134), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or sporadic and familial hemiplegic migraine.
- Receipt of any monoclonal antibody treatment (within or outside a clinical trial) within 6 months before screening.
- Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway.

A metabolic disease in which the body is unable to produce enough insulin (hormone) to control blood glucose (sugar)

Type 1: A condition where the body does not produce insulin or may destroy the insulin produced.

Type 2: Most common type of diabetes usually occurring in adulthood – but has increased in children due to obesity. A person’s body has a decreased ability to recognize and use the insulin produced.


Patients needed for hyperlipidemia study

To qualify:
Subject should have triglyceride levels between 500-2000
mg/dl and normal renal function

Study participants may be compensated for time and travel.


A condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health. Obesity is defined by a body mass index (BMI) exceeding 30 kg/m.

COPD Research Trial

COPD patients between 40-80 years old who are symptomatic

Must be receiving one or more inhaled bronchodilators as maintenance therapy

Must have a documented history of COPD exacerbations

Call: (312) 431-6780



The year Dr. Danny Sugimoto founded Cedar Crosse Research Center to make meaningful improvements in the lives of others through clinical research trials.


Number of clinical trials completed with a multi-specialty therapeutic expertise including diabetes, hypertension, obesity, COPD, migraines, hyperlipidemia, etc.


Average cycle time in days from IRB submittal to IRB approval.

of research


A personalized, patient centered perspective in all clinical tasks.


Strictly adhering to GCP and FDA regulatory procedures to quality date collections.


Uniting with patients to improve lives.

Randomization Rate


Contact us to request additional information or to make an appointment